Blog - QualityStocks

MondayApr 20, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The Intox Collect(TM) technology enhances the company’s ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment. MindBio says the platform broadens detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants. The company’s AI model currently uses more than 50 million data points, with management expecting that figure to increase further. MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. Target industries include mining, aviation,…

MondayApr 20, 2026 9:00 am

Beeline Holdings Inc. (NASDAQ: BLNE) Expands Embedded Mortgage Strategy Through SRG Partnership

Beeline is integrating its mortgage and title platform into a broader AI-driven real estate ecosystem, with embedded finance emerging as an important distribution model in residential real estate. The SRG partnership targets up to 2,000 home financings in a defined, multi-year development pipeline. The company’s AI tools aim to reduce friction in underwriting and borrower qualification, with younger buyers and real estate investors remaining a core demographic focus. Early share price performance suggests investor responsiveness to execution milestones and partnerships. Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, is advancing its…

FridayApr 17, 2026 2:10 pm

QualityStocksNewsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Deploys AI, Thermal Imaging to Redefine Rail Safety

Amid increased demand for advanced collision-avoidance systems as rail networks grow more complex, Rail Vision’s (NASDAQ: RVSN) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response. “Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the industry,” reads a recent article. “Rail Vision’s AI-powered electro-optical sensor systems are designed to address key railway safety challenges by integrating wide-field and narrow-field electro-optic cameras to provide a complete ‘safety envelope’ around the train. The company’s solutions include the use of thermal cameras that…

FridayApr 17, 2026 1:19 pm

QualityStocksNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear…

FridayApr 17, 2026 12:37 pm

QualityStocksNewsBreaks – Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”…

FridayApr 17, 2026 12:35 pm

QualityStocksNewsBreaks – Suntex Enterprises Inc. (OTC: SNTX) Reports Restructuring Completion and Simplified Capital Structure

Suntex Enterprises (OTC: SNTX) announced the filing of its annual financial statements, highlighting a completed operational restructuring and simplified capital structure with no outstanding debt or convertible instruments. The company also confirmed submission of a corporate action to FINRA seeking approval for a shareholder dividend tied to a diversified portfolio of operating businesses, as Suntex advances a strategy focused on scaling its subsidiaries through organic growth and acquisitions while targeting approximately $100 million in annual revenue and evaluating potential uplisting opportunities. To view the full press release, visit https://ibn.fm/pFJV1 About Suntex Enterprises, Inc. (OTC: SNTX) Suntex Enterprises, Inc. is a diversified…

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 11:30 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets. Lahontan is working to build value through continued drilling, metallurgical work and project advancement. The company is showing a steady stream of updates this year, including drilling and key financing. Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle,…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

FridayApr 17, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

Site Search

Company Search